CDK7 and renal cell carcinoma: In particular, we found that a CDK7 inhibitor, which is currently used in clinical trial, can effectively repress the expression of lncTCLF5-2, and enhance the efficacy of Sunitinib for RCC, further substantiating the notion that this lncRNA is critical for the CSCs phenotype as well as resistance to targeted therapy.